Literature DB >> 27429143

Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model.

Baruch E Bulvik1, Nir Rozenblum1, Svetlana Gourevich1, Muneeb Ahmed1, Alexander V Andriyanov1, Eithan Galun1, S Nahum Goldberg1.   

Abstract

Purpose To compare both periablational and systemic effects of two mechanistically different types of ablation: thermal radiofrequency (RF) ablation and electroporative ablation with irreversible electroporation (IRE) in appropriately selected animal models. Materials and Methods Animal experiments were performed according to a protocol approved by the Animal Care Committee of Hebrew University. Female C57BL/6 mice (n = 165) were randomized to undergo either RF or IRE ablation of noncancerous normal liver. The inflammatory response, cell proliferation, interleukin 6 (IL-6) levels, and intactness of vessels in the liver were assessed at 6, 12, and 24 hours and at 3, 7, and 14 days after ablation (n = 122 for mechanistic experiments). Systemic effects were then assessed by comparing tumor formation in an Mdr2-knockout (KO) mouse model (n = 15) and tumor growth in a remote BNL 1ME hepatoma xenograft tumor (n = 28). Results were averaged and evaluated by using two-tailed t tests. Results Although RF ablation was associated with a well-defined periablational inflammatory rim, for IRE, the infiltrate penetrated the ablation zone, largely along persistently patent vessels. Peak IL-6 levels (6 hours after ablation) were 10 and three times higher than at baseline for IRE and RF, respectively (P < .03). Mdr2-KO mice that were treated with IRE ablation had more tumors that were 3 mm or larger than mice treated with RF ablation or sham operation (mean, 3.6 ± 1.3 [standard deviation] vs 2.4 ± 1.1 and 2.2 ± 0.8, respectively; P < .05 for IRE vs both RF ablation and sham operation). For BNL 1ME tumors, both RF and IRE liver ablation reduced tumor growth, with a greater effect noted for IRE (1329 mm(3) ± 586 and 819 mm(3) ± 327 vs 2241 mm(3) ± 548 for sham operation; P < .05) that was accompanied by more infiltrating lymphocytes compared with sham operation (7.6 cells per frame ± 1.9 vs 11.2 ± 2.1 vs 0.3 ± 0.1; P < .05). Conclusion Persistent patency of vasculature within the coagulated zone from IRE increases the area and accumulation of infiltrative cells that is associated with a higher serum IL-6 level than RF ablation. These local changes of IRE induce more robust systemic effects, including both tumorigenic and immunogenic effects. (©) RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2016        PMID: 27429143     DOI: 10.1148/radiol.2015151166

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

Review 1.  Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation.

Authors:  Salvatore Paiella; Matteo De Pastena; Mirko D'Onofrio; Stefano Francesco Crinò; Teresa Lucia Pan; Riccardo De Robertis; Giovanni Elio; Enrico Martone; Claudio Bassi; Roberto Salvia
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-26

2.  Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.

Authors:  Pankaj Gupta; Muniraju Maralakunte; Sathya Sagar; Praveen Kumar-M; Harish Bhujade; Sreedhara B Chaluvashetty; Naveen Kalra
Journal:  Eur Radiol       Date:  2021-02-27       Impact factor: 5.315

3.  Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor Growth.

Authors:  Erik Velez; S Nahum Goldberg; Gaurav Kumar; Yuanguo Wang; Svetlana Gourevitch; Jacob Sosna; Tyler Moon; Christopher L Brace; Muneeb Ahmed
Journal:  Radiology       Date:  2016-07-13       Impact factor: 11.105

Review 4.  Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.

Authors:  Lin Mu; Julius Chapiro; Jeremiah Stringam; Jean-François Geschwind
Journal:  Cancer J       Date:  2016 Nov/Dec       Impact factor: 3.360

5.  Irreversible electroporation ablation of end-stage metastatic retroperitoneal lesions: Report on three cases and literature review.

Authors:  Tian'An Jiang; Qiyu Zhao; Guo Tian; Xinhua Chen; Liming Wu
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

6.  Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?

Authors:  Lucas Christoph Adam; Nikitha Murali; Julius Chapiro; Jean-François Geschwind
Journal:  Radiology       Date:  2017-11       Impact factor: 11.105

7.  Electroporation-induced changes in tumor vasculature and microenvironment can promote the delivery and increase the efficacy of sorafenib nanoparticles.

Authors:  Hiroshi Kodama; Yosef Shamay; Yasushi Kimura; Janki Shah; Stephen B Solomon; Daniel Heller; Govindarajan Srimathveeravalli
Journal:  Bioelectrochemistry       Date:  2019-07-06       Impact factor: 5.373

8.  Normal and fibrotic liver parenchyma respond differently to irreversible electroporation.

Authors:  Chenang Lyu; Maya Lopez-Ichikawa; Boris Rubinsky; Tammy T Chang
Journal:  HPB (Oxford)       Date:  2019-03-14       Impact factor: 3.647

Review 9.  Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Authors:  Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg
Journal:  Radiology       Date:  2019-04-23       Impact factor: 11.105

10.  Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins.

Authors:  Muneeb Ahmed; Gaurav Kumar; Svetlana Gourevitch; Tatyana Levchenko; Eithan Galun; Vladimir Torchilin; S Nahum Goldberg
Journal:  Int J Hyperthermia       Date:  2018-04-24       Impact factor: 3.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.